Efficacy and safety of temelimab in multiple sclerosis: Results of a randomized phase 2b and extension study

Hans Peter Hartung, Tobias Derfuss, Bruce A.C. Cree, Maria Pia Sormani, Krzysztof Selmaj, Jonathan Stutters, Ferran Prados, David MacManus, Hans Martin Schneble, Estelle Lambert, Hervé Porchet, Robert Glanzman, David Warne, Francois Curtin, Gabrielle Kornmann, Bénédicte Buffet, David Kremer, Patrick Küry, David Leppert, Thomas RückleFrederik Barkhof

Research output: Contribution to journalArticlepeer-review


Background: The envelope protein of human endogenous retrovirus W (HERV-W-Env) is expressed by macrophages and microglia, mediating axonal damage in chronic active MS lesions. Objective and Methods: This phase 2, double-blind, 48-week trial in relapsing-remitting MS with 48-week extension phase assessed the efficacy and safety of temelimab; a monoclonal antibody neutralizing HERV-W-Env. The primary endpoint was the reduction of cumulative gadolinium-enhancing T1-lesions in brain magnetic resonance imaging (MRI) scans at week 24. Additional endpoints included numbers of T2 and T1-hypointense lesions, magnetization transfer ratio, and brain atrophy. In total, 270 participants were randomized to receive monthly intravenous temelimab (6, 12, or 18 mg/kg) or placebo for 24 weeks; at week 24 placebo-treated participants were re-randomized to treatment groups. Results: The primary endpoint was not met. At week 48, participants treated with 18 mg/kg temelimab had fewer new T1-hypointense lesions (p = 0.014) and showed consistent, however statistically non-significant, reductions in brain atrophy and magnetization transfer ratio decrease, as compared with the placebo/comparator group. These latter two trends were sustained over 96 weeks. No safety issues emerged. Conclusion: Temelimab failed to show an effect on features of acute inflammation but demonstrated preliminary radiological signs of possible anti-neurodegenerative effects. Current data support the development of temelimab for progressive MS. Trial registration: CHANGE-MS: ClinicalTrials.gov: NCT02782858, EudraCT: 2015-004059-29; ANGEL-MS: ClinicalTrials.gov: NCT03239860, EudraCT: 2016-004935-18.

Original languageEnglish
JournalMultiple Sclerosis Journal
Publication statusAccepted/In press - 2021


  • atrophy
  • clinical trial
  • MRI
  • Temelimab

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology


Dive into the research topics of 'Efficacy and safety of temelimab in multiple sclerosis: Results of a randomized phase 2b and extension study'. Together they form a unique fingerprint.

Cite this